Servicio de Nefrología, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
Nefrologia. 2012;32(1):35-43. doi: 10.3265/Nefrologia.pre2011.Nov.11094.
Acute renal failure (ARF) occurs in 12%-20% of all multiple myeloma (MM) cases, and the survival of these patients depends on renal function recovery. Renal function is not recovered in 75% of dialysis-dependent patients, and their mean survival with replacement therapy is less than one year. Renal tubular disease is the most frequent cause of renal failure. It is present in more than 55% of renal failure cases and in 75% of those requiring dialysis. Rapid reduction of free light chain levels in the blood is necessary in order to recover renal function. One coadjuvant measure in treating the disease is reducing light chain levels with plasmapheresis, but its efficacy has not yet been clearly proven. Our proposal was therefore to use extended haemodialysis sessions with high cut-off dialysers (HCO-HD), obtaining a recovery rate of more than 60%. We present the progress of 6 patients with myeloma and acute renal failure who were treated with HCO-HD and the complications associated with using this type of haemodialysis. Then, we review the pros and cons of this technique.
Six patients diagnosed with MM and ARF requiring dialysis and with serum free light chain levels above 500 mg/l were treated with 8-hour haemodialysis sessions with an HCO-HD filter. Before and after each session, serum free light chain levels were measured by nephelometry; other parameters were recorded as well. At the same time, patients underwent chemotherapy according to protocols.
The symptom onset times of the 3 men and 3 women diagnosed with MM and ARF were highly variable, from 7 days to more than 1 year. We performed 90 extended sessions with HCO-HD filters, and each patient underwent between 6 and 40 sessions. Free light chain levels decreased by a mean of 65% between treatment onset and completion, except in one patient who experienced a 12.6% reduction. The mean percentage of reduction of light chain levels per session was 54.98% ± 17.27%. A complication occurred during 28% of the sessions. Of these complications, 48% were due to system coagulation. There were no major changes in pre-dialysis albumin, calcium, phosphorous or magnesium levels, although lower values that were not clinically relevant were recorded in one case. Renal function was recovered in 3 patients, they are alive and dialysis-free. In biopsied cases that recovered renal function, the specimen showed tubular nephropathy only. Those patients who took longer to be diagnosed did not recover their renal function, and when biopsied, they were diagnosed with renal tubular disease and light chain deposition disease.
We found extended haemodialysis with HCO-HD filters to be a reasonable alternative in ARF caused by renal tubular disease, and achieved a recovery rate of 50% in our cases. Function recovery was influenced by the elapsed time between symptom onset and myeloma diagnosis, histological findings, promptness of starting chemotherapy, response to chemotherapy, and effectiveness of light chain extraction. In any case, further studies are needed to examine new chemotherapy agents and new direct free light chain removal techniques.
急性肾衰竭(ARF)发生在所有多发性骨髓瘤(MM)病例的 12%-20%中,这些患者的生存取决于肾功能的恢复。75%依赖透析的患者肾功能无法恢复,接受替代治疗的患者平均生存时间不到一年。肾小管疾病是肾衰竭的最常见原因。它存在于超过 55%的肾衰竭病例中,也存在于 75%需要透析的病例中。为了恢复肾功能,必须快速降低血液中游离轻链的水平。治疗这种疾病的一种辅助措施是通过血浆置换降低轻链水平,但它的疗效尚未得到明确证实。因此,我们建议使用高通量透析器进行延长血液透析治疗,以获得超过 60%的恢复率。我们介绍了 6 例接受 HCO-HD 治疗的骨髓瘤合并急性肾衰竭患者的进展情况以及与使用这种类型血液透析相关的并发症。然后,我们回顾了这种技术的优缺点。
6 例诊断为 MM 并伴有 ARF 需要透析且血清游离轻链水平高于 500mg/L 的患者接受了 8 小时高通量透析器血液透析治疗。在每次治疗前后,通过散射比浊法测量血清游离轻链水平;同时记录其他参数。同时,根据方案对患者进行化疗。
3 名男性和 3 名女性患者的 MM 和 ARF 症状发作时间差异很大,从 7 天到 1 年以上不等。我们进行了 90 次 HCO-HD 过滤器的延长治疗,每个患者进行了 6-40 次治疗。游离轻链水平从治疗开始到结束平均降低了 65%,除了 1 例患者降低了 12.6%。每次治疗的轻链水平降低百分比平均为 54.98%±17.27%。28%的治疗过程中出现了并发症。这些并发症中,48%是由于系统凝血导致的。虽然有 1 例患者记录到的白蛋白、钙、磷或镁水平较低,但这些值没有临床意义。3 例患者肾功能恢复,他们存活且无需透析。在恢复肾功能的活检病例中,标本仅显示肾小管肾病。那些诊断时间较长的患者没有恢复肾功能,活检时被诊断为肾小管疾病和轻链沉积病。
我们发现,高通量透析器血液透析治疗是肾小管疾病引起的急性肾衰竭的一种合理选择,我们的病例恢复率为 50%。功能恢复受症状发作与骨髓瘤诊断之间时间间隔、组织学发现、开始化疗的及时性、化疗反应以及轻链提取效果的影响。在任何情况下,都需要进一步研究新的化疗药物和新的直接游离轻链清除技术。